SAFETY, PHARMACOKINETICS, AND ACTIVITY OF THE ANTI-NAPI2B ANTIBODY-DRUG CONJUGATE DNIB0600A: A PHASE I STUDY IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AND PLATINUM-RESISTANT OVARIAN CANCER

被引：0

作者：

Gerber, David ^{[1
]}

Infante, Jeffrey ^{[2
]}

Gordon, Michael ^{[3
]}

Schiller, Joan ^{[1
]}

Spigel, David ^{[4
]}

Wang, Yulei ^{[5
]}

Shames, David S. ^{[5
]}

Choi, Younjeong ^{[5
]}

Kahn, Robb ^{[5
]}

Xu, Jian ^{[5
]}

Lin, Kedan ^{[5
]}

Wood, Katie ^{[5
]}

Maslyar, Daniel ^{[5
]}

Burris, Howard ^{[4
]}

机构：

[1] UT Southwestern Med Ctr, Harold C Simmons Canc Ctr, Dallas, TX USA

[2] Tennessee Oncol Pllc, Sarah Cannon Res Inst, Nashville, TN USA

[3] Pinnacle Oncol Hematol, Scottsdale, AZ USA

[4] Sarah Cannon Res Inst, Nashville, TN USA

[5] Genentech Inc, San Francisco, CA USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷

关键词：

NSCLC; ADC; Phase I; NaPi2b;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P3.11-014

引用

页码：S1190 / S1191

页数：2

共 50 条

[1] Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer
Gerber, David E.
Infante, Jeffrey R.
Gordon, Michael S.
Goldberg, Sarah B.
Martin, Miguel
Felip, Enriqueta
Martinez Garcia, Maria
Schiller, Joan H.
Spigel, David R.
Cordova, Julie
Westcott, Valerie
Wang, Yulei
Shames, David S.
Choi, YounJeong
Kahn, Robert
Dere, Randall C.
Samineni, Divya
Xu, Jian
Lin, Kedan
Wood, Katie
Royer-Joo, Stephanie
Lemahieu, Vanessa
Schuth, Eva
Vaze, Anjali
Maslyar, Daniel
Humke, Eric W.
Burris, Howard A., III
CLINICAL CANCER RESEARCH, 2020, 26 (02) : 364 - 372
[2] PHARMACOKINETICS OF ANTIBODY-DRUG CONJUGATE (ADC)-DNIB0600A IN A PHASE I STUDY IN PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCER (OC)/NON-SMALL CELL LUNG CANCER (NSCLC).
Xu, J.
Burris, H., III
Gordon, M.
Gerber, D.
Choi, Y.
Lin, K.
Maslyar, D.
Girish, S.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S32 - S32
[3] A phase I study of the safety and pharmacokinetics of DNIB0600A, an anti-NaPi2b antibody-drug-conjugate (ADC), in patients (pts) with non- small cell lung cancer (NSCLC) and platinum-resistant ovarian cancer (OC).
Gordon, Michael S.
Gerber, David E.
Infante, Jeffrey R.
Xu, Jian
Shames, David S.
Choi, Younjeong
Kahn, Robert S.
Lin, Kedan
Wood, Katie
Maslyar, Daniel J.
Burris, Howard A.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[4] A phase I study of DNIB0600A, an antibody-drug conjugate (ADC) targeting NaPi2b, in patients (pts) with non-small cell lung cancer (NSCLC) or platinum-resistant ovarian cancer (OC)
Burris, Howard A.
Gordon, Michael S.
Gerber, David E.
Spigel, David R.
Mendelson, David S.
Schiller, Joan H.
Wang, Yulei
Choi, Younleong
Kahn, Robert S.
Wood, Katie
Maslyar, Daniel J.
Infante, Jeffrey R.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[5] Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer
Moore, Kathleen N.
Birrer, Michael J.
Marsters, Jim
Wang, Yulei
Choi, YounJeong
Royer-Joo, Stephanie
Lemahieu, Vanessa
Armstrong, Katy
Cordova, Julie
Samineni, Divya
Schuth, Eva
Vaze, Anjali
Maslyar, Daniel
Humke, Eric W.
Hamilton, Erika P.
Liu, Joyce F.
GYNECOLOGIC ONCOLOGY, 2020, 158 (03) : 631 - 639
[6] Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study
Banerjee, S.
Oza, A. M.
Birrer, M. J.
Hamilton, E. P.
Hasan, J.
Leary, A.
Moore, K. N.
Mackowiak-Matejczyk, B.
Pikiel, J.
Ray-Coquard, I.
Trask, P.
Lin, K.
Schuth, E.
Vaze, A.
Choi, Y.
Marsters, J. C.
Maslyar, D. J.
Lemahieu, V.
Wang, Y.
Humke, E. W.
Liu, J. F.
ANNALS OF ONCOLOGY, 2018, 29 (04) : 917 - 923
[7] A randomized, open-label, phase II study of anti-NaPi2b antibody-drug conjugate (ADC) lifastuzumab (Lifa) vedotin (DNIB0600A) compared to pegylated liposomal doxorubicin (PLD) in patients (pts) with platinum-resistant ovarian cancer (PROC).
Banerjee, Susana N.
Oza, Amit M.
Birrer, Michael J.
Hamilton, Erika Paige
Hasan, Jurjees
Leary, Alexandra
Moore, Kathleen N.
Mackowiak-Matejczyk, Beata
Pikiel, Joanna
Ray-Coquard, Isabelle
Trask, Peter
Lin, Kedan
Vaze, Anjali
Choi, YounJeong
Marsters, Jim
Maslyar, Daniel J.
Lemahieu, Vanessa
Wang, Yulei
Humke, Eric William
Liu, Joyce F.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[8] Preclinical Development of an Anti-NaPi2b (SLC34A2) Antibody-Drug Conjugate as a Therapeutic for Non-Small Cell Lung and Ovarian Cancers
Lin, Kedan
Rubinfeld, Bonnee
Zhang, Crystal
Firestein, Ron
Harstad, Eric
Roth, Leslie
Tsai, Siao Ping
Schutten, Melissa
Xu, Keyang
Hristopoulos, Maria
Polakis, Paul
CLINICAL CANCER RESEARCH, 2015, 21 (22) : 5139 - 5150
[9] Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer
Liu, J. F.
Moore, K. N.
Birrer, M. J.
Berlin, S.
Matulonis, U. A.
Infante, J. R.
Wolpin, B.
Poon, K. A.
Firestein, R.
Xu, J.
Kahn, R.
Wang, Y.
Wood, K.
Darbonne, W. C.
Lackner, M. R.
Kelley, S. K.
Lu, X.
Choi, Y. J.
Maslyar, D.
Humke, E. W.
Burris, H. A.
ANNALS OF ONCOLOGY, 2016, 27 (11) : 2124 - 2130
[10] Targeting MUC16 with the antibody-drug conjugate (ADC) DMUC5754A in patients with platinum-resistant ovarian cancer: A phase I study of safety and pharmacokinetics.
Liu, Joyce
Moore, Kathleen
Birrer, Michael
Berlin, Suzanne
Matulonis, Ursula
Infante, Jeffrey
Xi, Jian
Kahn, Robert
Wang, Yulei
Wood, Katie
Coleman, Daniel
Maslyar, Daniel
Humke, Eric
Burris, Howard
CANCER RESEARCH, 2013, 73 (08)

← 1 2 3 4 5 →